— Know what they know.
Not Investment Advice

GENO.ST STO

Genovis AB
1W: +3.0% 1M: -9.1% 3M: +1.8% YTD: -0.4% 1Y: -19.8% 3Y: -55.9% 5Y: -65.0%
kr 19.54 ($1.95)
-0.14 (-0.71%)
 
Weekly Expected Move ±4.8%
kr 18 kr 19 kr 20 kr 20 kr 21
STO · Healthcare · Biotechnology · Tech Score Neutral · Power 49 · kr 1.3B mcap · 57M float · 0.189% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Capkr 1.3B ($128.7M)
52W Range15.64-24.5
Volume216,696
Avg Volume106,868
Beta1.73
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFredrik Olsson
Employees42
SectorHealthcare
IndustryBiotechnology
IPO Date2017-04-28
Box 4
Kävlinge, SN 244 21
SE
46 46 10 12 30
About Genovis AB

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms